# A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

> **NCT07725939** · PHASE2 · RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 402 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

## Interventions

- **BIOLOGICAL:** Galvokimig
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07725939
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-27
- **Primary completion:** 2029-06-29
- **Final completion:** 2029-06-29
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725939, "A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07725939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*